Hims & Hers Health, Inc. (HIMS)
| Market Cap | 6.73B +7.7% |
| Revenue (ttm) | 2.37B +32.8% |
| Net Income | -13.24M |
| EPS | -0.06 |
| Shares Out | 231.07M |
| PE Ratio | 56.88 |
| Forward PE | 50.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,845,148 |
| Open | 29.09 |
| Previous Close | 28.27 |
| Day's Range | 28.55 - 30.39 |
| 52-Week Range | 13.74 - 70.43 |
| Beta | 2.42 |
| Analysts | Buy |
| Price Target | 29.75 (+2.06%) |
| Earnings Date | May 11, 2026 |
About HIMS
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and de... [Read more]
Financial Performance
In 2025, Hims & Hers Health's revenue was $2.35 billion, an increase of 59.00% compared to the previous year's $1.48 billion. Earnings were $128.37 million, an increase of 1.85%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for HIMS stock is "Buy." The 12-month stock price target is $29.75, which is an increase of 2.06% from the latest price.
News
Notable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Hims & Hers (HIMS), consensus 3c… GoPro (GPRO), consensus (4c)… Rigetti Computing (RGTI), consensus (4c)… ZoomInfo ...
Hims & Hers Health reports Q1 EPS (40c) vs 20c last year
Reports Q1 revenue $608.1M, consensus $616.85M. “2026 is a defining year for Hims & Hers. We’re not just growing, we’re pulling away from the field on our path to becoming…
Hims & Hers Health sees Q2 revenue $680M-$700M, consensus $642.94M
Sees Q2 adjusted EBITDA $35M-$55M.
Hims & Hers Health raises FY26 revenue view to $2.8B-$3B from $2.7B-$2.9B
Consensus $2.72B. Cuts FY26 adjusted EBITDA view to $275M-$350M from $300M-$375M.
Hims & Hers Health Swings to First-Quarter Loss as Expenses Rise
The telehealth platform posted a quarterly loss of $92.1 million, offsetting a 4% increase in revenue.
Hims & Hers Health Earnings Call Transcript: Q1 2026
Q1 2026 saw 4% revenue growth to $608M and a strategic pivot to branded weight loss products, driving record new subscribers but incurring $33M in restructuring costs. Full-year revenue guidance was raised to $2.8B–$3B, with continued investment in technology and international expansion.
Hims & Hers Stock Sinks. Why Earnings Offered Wall Street A Big Surprise.
Hims & Hers shares are falling after reporting disappointing first-quarter earnings results.
Hims & Hers raises 2026 revenue forecast on strong demand for personalized care
Hims & Hers Health raised its 2026 revenue forecast on Monday, betting on increased sales for its personalized healthcare offerings.
Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the first quarter...
Polymarket Earnings: Will HIMS, CRCL, QUBT Beat Earnings on Monday?
On Monday, May 11, Hims & Hers Health ($HIMS), Circle ($CRCL), and Quantum Computing ($QUBT) will report their earnings. Circle will report before the market open, while Hims & Hers and…
HIMS Stock Options Traders Are Pricing In a Huge Price Swing after Earnings
Hims & Hers Health ($HIMS) stock options traders are pricing in a sharp move ahead of the healthcare company’s earnings. With the stock trading around $26.25, we will use the…
Hims & Hers (HIMS) Set to Report Q1 Earnings — Here’s What Analysts Expect
Hims & Hers Health ($HIMS) will report its Q1 2026 earnings on May 11. The telehealth company heads into earnings with strong recent momentum, with HIMS stock gaining more than…
Mixed options sentiment in Hims and Hers Health with shares down 3.44%
Mixed options sentiment in Hims and Hers Health (HIMS), with shares down 92c near $25.95. Options volume relatively light with 35k contracts traded and calls leading puts for a put/call…
Moderately bullish activity in Hims and Hers Health with shares down 1.2%
Moderately bullish activity in Hims and Hers Health (HIMS), with shares down 33c near $27.08. Options volume relatively light with 70k contracts traded and calls leading puts for a put/call…
Mixed options sentiment in Hims and Hers Health with shares down 4.95%
Mixed options sentiment in Hims and Hers Health (HIMS), with shares down $1.46 near $27.93. Options volume relatively light with 147k contracts traded and calls leading puts for a put/call…
Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the ...
Bullish flow in Hims and Hers Health with shares up 9.2%
Bullish flow in Hims and Hers Health (HIMS), with shares up $2.59, or 9.2%, near $30.74. Options volume running well above average with 243k contracts traded and calls leading puts…
Now Is the Time to Buy Hims & Hers Stock (HIMS), Says JPMorgan Chase
Weight-loss drugs could be a big revenue generator.
Hims & Hers expands into menopause care as estrogen patch demand rises
Telehealth company Hims & Hers said on Wednesday it will now offer treatment options for perimenopause and menopause via its platform, as rising U.S. demand for hormone therapy strains supplies of e...
RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Investors are starting to focus on what will replace compounded GLP-1 driven growth for telehealth companies like Hims & Hers Health. Peptides are gaining attention as a potential new growth vector, d...
Hims rises as FDA considers broader peptides access; analysts see long-term win
Shares of Hims & Hers Health rose more than 7% on Thursday as analysts said the U.S. drug regulator's consideration to allow compounding pharmacies to manufacture popular peptides could benefit the t...
Hims & Hers surges 4% as peptide policy shift unlocks growth
Shares of Hims & Hers Health moved sharply higher on Thursday, extending gains from the previous session after a significant regulatory shift signaled new opportunities in the peptide market. The stoc...
Hims & Hers Health Stock Rallies on Regulatory Pivot. It's Not About GLP-1s This Time.
Hims has signaled its interest in peptides, many of which have been banned for use in compounding pharmacies.
Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides
Hims & Hers Health's plan to enter the business of selling peptides is looking a lot more realistic.